MedicalResearch.com - Latest news, interviews, and insights into medical research, health and wellness, fitness and addiction.
Author Interviews, Cancer Research, Dental Research, JAMA, Microbiome, NYU, Pancreatic / 13.10.2025

MedicalResearch.com Interview with: Jiyoung Ahn, PhD Professor of Population Health, NYU Grossman School of Medicine Associate Director for Population Science, NYU Perlmutter Cancer Center NYU Langone Health New York, NY 10016 MedicalResearch.com: What is the background for this study? Response: About 10 years ago. we reported that people with poor oral health seem to have a greater risk of pancreatic cancer development.  We suspected that this could be due to oral microbiota.  More recently, animal studies, by other groups, showed that bacteria from the mouth can actually travel through saliva into the pancreas. But we didn’t know which exact species of bacteria or fungi might be involved in pancreas cancer development. We therefore conducted this large human study to examine the oral microbiome — including whole bacteria and fungi profiles in the mouth, and to see which bacteria and fungal taxa are associated with subsequent risk of pancreatic cancer development. (more…)
Author Interviews, Cancer Research, Nature, NYU, Pancreatic / 17.03.2023

MedicalResearch.com Interview with: Aristotelis Tsirigos, Ph.D. Professor of Medicine and Pathology Co-director, Precision Medicine Director, Applied Bioinformatics LaboratoriesNew York University School of Medicine MedicalResearch.com: What is the background for this study? Response: Pancreatic cancer is one of the most lethal types of cancer with only 12% of patients surviving more than 5 years after diagnosis. One of the main reasons behind the dismal prognosis is the complexity of the tumor. Pancreatic cancer cells are very heterogenous and interact with different types of non-malignant cells in what is known as the tumor microenvironment. (more…)
Author Interviews, Cancer Research, Nature, Pancreatic, University of Michigan / 03.06.2022

MedicalResearch.com Interview with: Imad Shureiqi, MD, MS Professor, Division of Hematology and Oncology Department of Internal Medicine Rogel Cancer Center Ann Arbor, MI, 48109 MedicalResearch.com:  What is the background for this study?   Response: Pancreatic ductal adenocarcinoma is a highly lethal form of cancer with rising occurrence, and strategies to prevent and treat the disease are urgently needed. Most cases of pancreatic cancer arise from pre-cancerous lesions called pancreatic intraepithelial neoplasia (PanIN); about 55-80% of adults over forty are estimated to have these low-grade pre-cancerous silent pancreatic lesions. But critical factors that promote the progression of pancreatic pre-cancerous lesions to pancreatic cancer remain poorly defined, especially those easy to target. Findings from this publication indicate that people who have silent PanIN pre-cancerous lesions, even those that are low-grade, could increase their risk of PanIN progression into pancreatic cancer by consuming activators of a nuclear lipid receptor called peroxisome proliferator-activated receptor-delta (PPARδ). PPARδ activators can be natural substances, such certain fatty acids like palmitic and arachidonic acid in high-fat diets, or synthetic ones, like Cardarine (GW501516). (more…)
Author Interviews, Biomarkers, BMJ, Gastrointestinal Disease, Pancreatic / 09.03.2022

MedicalResearch.com Interview with: Ece Kartal, PhD Postdoctoral Fellow Saez-Rodriguez Group Universitätsklinikum Heidelberg Institute for Computational Biomedicine Heidelberg MedicalResearch.com:  What is the background for this study?    Response: Pancreatic cancer is one of the deadliest types of cancer: although incidence rates are relatively low (only few people develop pancreatic cancer in their lifetimes), it has a high lethality, with a five year survival rate of less than ~5%. Pancreatic cancer symptoms are generally unspecific so that the disease is usually detected very late which further  limits therapeutic options. In light of this, earlier detection of pancreatic cancer could dramatically improve prognosis, but there are currently no affordable and non-invasive tests available in the clinic. For pancreatic ductal adenocarcinoma (PDAC),the most common form of pancreatic cancer, it was previously found that the oral, gut and pancreatic microbiome are risk factors and may affect prognosis . (more…)
Author Interviews, Gender Differences, Pancreatic, Race/Ethnic Diversity / 23.05.2021

MedicalResearch.com Interview with: Kelly Herremans, MD Lead researcher on the study Surgical research fellow University of Florida College of Medicine Gainesville MedicalResearch.com: What is the background for this study? Response: Pancreatic cancer is a deadly malignancy with an estimated 5-year survival rate of only 9%. Significant racial and ethnic disparities exist in pancreatic cancer. Underrepresentation in the clinical trials that determine safety and efficacy may contribute to these disparate outcomes. (more…)